Related Experiment Videos

Modulation of [3H]glibenclamide binding to cardiac and insulinoma membranes

J F French1, L C Riera, U L Mullins

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, Cardiovascular Pharmacology, Wallingford, CT 06492.

Insights

This study reveals glibenclamide binds to both high and low affinity sites in insulinoma cells, suggesting multiple binding populations. G-proteins, cations, and pH influence this binding, warranting further investigation into its physiological relevance.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Biochemistry

Background:

  • The precise number and affinity of glibenclamide binding sites remain debated.
  • Glibenclamide is a key drug used in treating type 2 diabetes.

Purpose of the Study:

  • To investigate the existence of multiple [3H]glibenclamide binding sites in pancreatic tumor (insulinoma) cells.
  • To characterize glibenclamide binding in insulinoma and cardiac membranes.

Main Methods:

  • Radioligand binding assays using [3H]glibenclamide.
  • Analysis of glibenclamide binding in insulinoma and cardiac membranes under varying conditions (nucleotides, cations, pH).

Main Results:

  • [3H]Glibenclamide identified both high (0.1 nM) and low (240 nM) affinity binding sites in insulinoma membranes.
  • Guanine nucleotides, but not adenine nucleotides, modulated glibenclamide binding, suggesting G-protein involvement.
  • Divalent cations (Ca2+, Zn2+, Mg2+, Mn2+) and pH influenced glibenclamide binding differently in cardiac and insulinoma membranes.

Conclusions:

  • Evidence suggests multiple glibenclamide binding sites exist in insulinoma cells.
  • Glibenclamide binding is modulated by G-proteins, divalent cations, and pH.
  • The physiological significance of these findings requires further exploration.

Related Concept Videos